EuroPCR 2020 | Aortic Valve in Valve in the Long Term

The outcomes of this work are important to plan valve replacement with the largest possible prosthesis allowed by patient anatomy in the index procedure.

EuroPCR 2020 | Valve in Valve aórtico a largo plazo

As a worldwide trend, increasingly more patients are receiving bioprostheses, which have improved a lot but still tend to become deteriorated and require a valve-in-valve procedure if the patient is no longer a suitable candidate for surgery.

One of the main differences compared with conventional transcatheter aortic valve replacement is that valve-in-valve procedures tend to finish with residual gradient, which might affect the long-term durability of the prosthesis.

This work, presented at the virtual EuroPCR 2020 and simultaneously published in the European Heart Journal, analyzed 1006 valve-in-valve procedures from the VIVID registry. Mean patient age was 77.7 years old and the mean Society of Thoracic Surgeons (STS)-PROM score was 7.3%.

About half (52%) of patients received self-expanding valves (CoreValve or Evolut), and 43.2% received balloon-expandable prostheses of any generation (Sapien/Sapien XT/S3).


Read also: EuroPCR 2020 | FABOLUS FASTER: In the Quest for the Fastest, Most Potent Platelet Inhibition.


Survival at 8 years was 38% overall, but, comparing patients with small (internal diameter <20 mm) and large failed prostheses, survival was lower with smaller devices (33.2% vs. 40.5%; p = 0.01).

Smaller failed bioprostheses, age, lower ejection fraction, chronic kidney disease, diabetes, and nontransfemoral access were all independent predictors of mortality. The factors associated with reintervention were pre-existing severe patient prosthesis mismatch, device suboptimal implantation, age, and balloon-expandable valve use.

During the same EuroPCR session, researchers presented an update on the BASILICA registry. BASILICA is a technique that involves lacerating the preexisting aortic leaflet (native or failed prosthetic) with radiofrequency immediately before new prosthesis implantation in patients at high risk for coronary obstruction.


Read also: EuroPCR 2020 | Sudden Death Increase Two to Three Times While MI Rate Falls.


Now, the presentation reported 129 successful cases with the aforementioned procedure, including 22 cases of double BASILICA (both left- and right-sided leaflets were lacerated).

The technique was associated with a higher risk of stroke, compared with controls, but a lower risk of coronary obstruction and of 30-day mortality, stroke, and coronary obstruction, as a composite. The double BASILICA technique had a bad prognosis, as opposed to the laceration of a single leaflet.

valve-in-valve-ao-a-largo-plazo

Título original: Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves.

Presentador: Danny Dvir. Eur Heart J. 2020; Epub ahead of print y presentado en forma virtual en el EuroPCR 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring

Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...

AHA 2025 | CLOSURE-AF: Left Atrial Appendage Occlusion (LAAO) vs. Medical Therapy in Atrial Fibrillation with High Stroke and Bleeding Risk

Atrial fibrillation (AF) is a complex condition in which patients often present with multiple comorbidities, including high bleeding risk. Percutaneous left atrial appendage occlusion...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

TCT 2025 | ANDES Trial: Short-Term DOAC vs. DAPT After Percutaneous Left Atrial Appendage Occlusion

Percutaneous left atrial appendage occlusion (LAAO) is an established alternative to chronic anticoagulation in patients with non-valvular atrial fibrillation (AFib). A clinically relevant complication...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring

Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...